Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.6/5
Antengene (6996 HK)
Watchlist
44
Analysis
Health Care
•
China
Antengene Corporation Limited operates as a specialty pharmaceutical company. The Company produces innovative drugs, selinexor, eltanexor, verdinexor, and other products. Antengene provides its services throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Remegen
•
28 Feb 2021 06:00
HSCI Index Rebalance & Stock Connect: Inclusions & Exclusions
There are 36 inclusions/ 29 exclusions for the Hang Seng Composite Index. 9 stocks will be deleted from the Stock Connect Buy list & there are a...
Brian Freitas
Follow
560 Views
Share
bullish
•
Thematic (Sector/Industry)
•
07 Feb 2021 01:31
China Healthcare Weekly (Feb.5)
This article analyzed the results of the 4th volume-based purchase, the CTLA-4 antibody drug industry, the orthopedic implant device market, news...
Xinyao (Criss) Wang
Follow
293 Views
Share
bullish
•
Thematic (Sector/Industry)
•
01 Feb 2021 01:33
China Healthcare Weekly (Jan.29)
The article analyzed industry viewpoints in terms of IBD drug therapy, import substitution for reagent varieties and high-end antibiotics market,...
Xinyao (Criss) Wang
Follow
310 Views
Share
bullish
•
BeiGene
•
12 Jan 2021 18:26
BeiGene: Novartis Grabs Tislelizumab Rights
BeiGene's deal with Novartis for PD-1 tislelizumab validates its competitive position, and marks a rising trend of Chinese companies licensing...
Kemp Dolliver, CFA
326 Views
Share
bullish
•
Thematic (Sector/Industry)
•
11 Jan 2021 01:30
China Healthcare Weekly (Jan.8)
The article analyzed the viewpoints in neurointerventional medical devices market, orthokeratology lenses market and pet medical market in China,...
Xinyao (Criss) Wang
Follow
284 Views
Share
First
Previous
2
3
4
5
6
7
8
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10
x